Andrew Pasternak

Forward Water Technologies, Inc. is a Canadian company that specializes in the commercialization of its proprietary forward osmosis technology. The company was founded in 2012 by Greencentre and is based on a platform technology developed at Queen's University in Kingston. The company's focus is on large-scale implementation of its technology in industrial wastewater, oil and gas, mining, agriculture, and municipal water supply and re-use market sectors. The company is based in Mississauga, Canada. The technology allows for the reduction of challenging waste streams with high levels of dissolved salts while simultaneously returning fresh water for re-use or surface release. C. Howie Honeyman has been the CEO of the company since 2015.

GreenCentre Canada manufactures chemical products. It offers technologies that have been in-licensed, iron catalysts for fine polymers and chemical compounds catalytic hydrogenation of esters and dehydrogenative coupling of alcohols eco-friendly biocide for coatings switchable water high performance catalysts for biodegradable polyesters metal-free hydrogenation catalysts carboxylic acid amidation 'gemini' multi-purpose surfactants precursors for atomic layer deposition. The company was founded in 2009 and is headquartered in Kingston, the United Kingdom.

MDS Sciex manufactures and supplies industrial equipment. The company is headquartered in Concord, Canada.

Protana, Inc. provides pharmaceutical and biotechnology research services. It provides protein identification, protein interaction mapping, differential analysis, biomarker discovery, chemical proteomics, and insilico drug design services. The company provides services to medical and biopharmaceutical companies. The company headquartered in Toronto, Canada.

Transition Therapeutics, Inc. develops novel therapeutics for disease indications. It operates through research and development of therapeutic agents segment. The firm's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada.